Rising Stars Outlook 2016 :New Emergence of Potential Tx & Dx Options could transform the Current Landscape for Liver Diseases (NASH)
Table of Contents
1. Conatus Pharmaceuticals (CNAT)
Emricasan: Disease Modifying Potential across the Spectrum of Liver Diseases
- KEY MILESTONES (CNAT)
- 2. Trends in overall population driven by significant improvement in MELD =15 subgroup
Figure 1
Conatus Pharma
EMRICASAN: DATA FROM PHII, LIVER CIRRHOSIS TRIAL (3-MONTH
- Table 1
Conatus Pharma
PHIIB, ENCORE PROGRAM IN DIFFERENT ETIOLOGIES & STAGES
- Table 2
Conatus Pharma
COMPETITIVE LANDSCAPE (LATE-STAGE PIPELINE) FOR NASH
- Figure 2
Conatus Pharma
EMRICASAN: MEDICAL NEED AND MARKET OPPORTUNITIES
- Figure 3
Conatus Pharma
EMRICASAN: A POTENT INHIBITOR OF APOPTOTIC AND INFLAMMATORY CASPASES
- Figure 4
Conatus Pharma
EMRICASAN: PHASE II, LIVER CIRRHOSIS TRIAL (3 MONTHS)
- Figure 5
Conatus Pharma
EMRICASAN: PHASE II DATA @ EASL, 2015
- Figure 6
Conatus Pharma
EMRICASAN: PHASE II DATA @ AASLD, 2015
- Changes in Clinical, Biochemical, and Biomarker parameter from Baseline
2. Galectin Therapeutics (GALT)
- Reversing Late-Stage NASH (Advanced Fibrosis)
-KEY MILESTONES (GALT)
- COMPETITIVE LANDSCAPE (LATE-STAGE PIPELINE) FOR NASH
-ROLE OF GALECTIN-3 IN PATHOPHYSIOLOGY OF NASH AND FIBROGENESIS
- PHASE II TRIAL DESIGNS: NASH-CX (W/ CIRRHOSIS) & NASH-FX (W/ ADVANCED FIBROSIS)
- GR-MD-02: PHI STUDY - SERUM BIOMARKERS EVALUATION
- Figure 4
Galectin Therapeutics
GR-MD-02: PRECLINICAL DATA - TX EFFECT ON NASH WITH FIBROSIS
- Figure
Galectin Therapeutics
PIPELINE PORTFOLIO
3. Galmed Pharmaceuticals (GLMD)-Aramchol: A Differentiated Approach, Targeting Early NASH and Potentially, NAFL Pts
- KEY MILESTONES (GLMD)
- Table 1
Galmed Pharmaceuticals
COMPETITIVE LANDSCAPE (LATE-STAGE PIPELINE) FOR NASH
- Figure 1
Galmed Pharmaceuticals
ARAMCHOL: PHASE IIA DATA - RELATIVE CHANGE IN LIVER-FAT CONCENTRATION
- Figure 2
Galmed Pharmaceuticals
ARAMCHOL: DIFFERENTIATED MODE OF ACTION
- Figure 3
Galmed Pharmaceuticals
ARAMCHOL: CLINICAL TRIALS AND ITS ENDPOINTS
- Figure 4
Galmed Pharmaceuticals
PHIIA RESULTS: CHANGES IN CHOLESTEROL AND SERUM ADIPONECTIN LEVELS
- Figure 5
Galmed Pharmaceuticals
CHANGES IN THE LEVELS OF CHOLESTEROL CRYSTALLIZATION AFTER THE ADDITION OF ARAMCHOL
4. Genfit SA (GNFT)
- GNFT offers Remarkable NASH Treatment Package: Robust Drug + Non-Invasive Biomarker Test
- KEY MILESTONES (GNFT)
- Figure 1
Genfit SA
GOLDEN-505: COMPARISON WITH OTHER PHII STUDIES
- Figure 2
Genfit SA
GOLDEN-505: COMPARISON WITH OTHER PHII STUDIES
- Table 1
Genfit SA
COMPETITIVE LANDSCAPE (LATE-STAGE PIPELINE) FOR NASH
- Table 1
Genfit SA - Continued?
COMPETITIVE LANDSCAPE (LATE-STAGE PIPELINE) FOR NASH
- Figure 3
Genfit SA
ELAFIBRANOR: PPAR REGULATES NUMEROUS PATHWAYS ESSENTIAL IN NASH
- CLINICAL DEVELOPMENT
-Figure 4
Genfit SA
ELAFIBRANOR: PHASE III TRIAL DESIGN
- Figure 5A
Genfit SA
GOLDEN-505: IMPROVEMENT IN CARDIO-METABOLIC AND GLYCEMIC PARAMETERS
- Figure 6
Genfit SA
EFFICACY OF GFT505 IN ANIMAL MODELS OF NAFLD/ NASH AND LIVER FIBROSIS
- Figure 7
Genfit SA
EFFICACY OF GFT505 IN ANIMAL MODELS OF NAFLD/ NASH AND LIVER FIBROSIS
- Figure 8
Genfit SA
EFFECTS OF GFT505 IN RATS WITH ESTABLISHED HEPATIC FIBROSIS
- Figure 8
Genfit SA - Continued?
EFFECTS OF GFT505 IN RATS WITH ESTABLISHED HEPATIC FIBROSIS
5. Intercept Pharmaceuticals (ICPT)
- Mixed Data and Pricing/Reimbursement Concerns may Limit OCA's Market Potential
- Figure 1
Intercept Pharmaceuticals
GLOBAL PBC PATIENT WATERFALL
- KEY MILESTONES (ICPT)
- Figure 2
Intercept Pharmaceuticals
FLINT STUDY RESULTS: IMPROVEMENT IN NAS, FIBROSIS, AND NASH RESOLUTION
- Table 1
Intercept Pharmaceuticals
COMPETITIVE LANDSCAPE (LATE-STAGE PIPELINE) FOR NASH
- Figure 3
Intercept Pharmaceuticals
FXR IS CENTRAL TO A MULTITUDE OF PATHWAYS
- Figure 5
Intercept Pharmaceuticals
POISE STUDY: MET THE PRIMARY ENDPOINT AS EARLY AS 2 WEEKS
- Figure 6
FLINT STUDY: RESPONSE RATES, FIBROSIS IMPROVEMEN
- KEY MILESTONES
6 Tobira Therapeutics
CENTAUR - PHIIB CLINICAL TRIAL VS. OTHER PUBLISHED PHIIB STUDIES IN NASH
(TBRA)
Tobira Therapeutics
CENICRIVIROC (CVC): A POTENT INHIBITOR OF INFILTRATION OF PRO-INFLAMMATORY MONOCYTES
Tobira Therapeutics
DRUGS IN DEVELOPMENT FOR NASH
List of Tables
KEY MILESTONES (CNAT)
Gelectin Therapeutics : Key Milestone Table
Table1
Conatus Pharma
PHIIB, ENCORE PROGRAM IN DIFFERENT ETIOLOGIES & STAGES
Table 2
Conatus Pharma
COMPETITIVE LANDSCAPE (LATE-STAGE PIPELINE) FOR NASH
Table 1
Galectin Therapeutics
COMPETITIVE LANDSCAPE (LATE-STAGE PIPELINE) FOR NASH
Galmed - Key Milestone Table
Table 1
Galmed Pharmaceuticals
COMPETITIVE LANDSCAPE (LATE-STAGE PIPELINE) FOR NASH
Table 1
Genfit SA
COMPETITIVE LANDSCAPE (LATE-STAGE PIPELINE) FOR NASH
Intercept : Key Milestone Table
Table 1
Intercept Pharmaceuticals
COMPETITIVE LANDSCAPE (LATE-STAGE PIPELINE) FOR NASH
Table 1
Tobira Therapeutics
DRUGS IN DEVELOPMENT FOR NASH
Table 2
Tobira Therapeutics
CENICRIVIROC (CVC): PHIIB DATA IN HIV PTS - FAVORABLE 48-WEEK SAFETY (COMBINED WITH FTC/TDF)
List of Figures
Figure 1
Conatus Pharma
EMRICASAN: DATA FROM PHII, LIVER CIRRHOSIS TRIAL (3-MONTHS)
Figure 2
Conatus Pharma
EMRICASAN: MEDICAL NEED AND MARKET OPPORTUNITIES
Figure 3
Conatus Pharma
EMRICASAN: A POTENT INHIBITOR OF APOPTOTIC AND INFLAMMATORY CASPASES
Figure 4
Conatus Pharma
EMRICASAN: PHASE II, LIVER CIRRHOSIS TRIAL (3 MONTHS)
Figure 5
Conatus Pharma
EMRICASAN: PHASE II DATA @ EASL, 2015
Figure 6
Conatus Pharma
EMRICASAN: PHASE II DATA @ AASLD, 2015
Figure 1
Galectin Therapeutics
ROLE OF GALECTIN-3 IN PATHOPHYSIOLOGY OF NASH AND FIBROGENESIS
Figure 2
Galectin Therapeutics
PHASE II TRIAL DESIGNS: NASH-CX (W/ CIRRHOSIS) & NASH-FX (W/ ADVANCED FIBROSIS
Figure 3
Galectin Therapeutics
GR-MD-02: PHI STUDY - SERUM BIOMARKERS EVALUATION
Figure 4
Galectin Therapeutics
GR-MD-02: PRECLINICAL DATA - TX EFFECT ON NASH WITH FIBROSIS
Figure
Galectin Therapeutics
PIPELINE PORTFOLIO
Figure 1
Galmed Pharmaceuticals
ARAMCHOL: PHASE IIA DATA - RELATIVE CHANGE IN LIVER-FAT CONCENTRATION
Figure 2
Galmed Pharmaceuticals
ARAMCHOL: DIFFERENTIATED MODE OF ACTION
Figure 3
Galmed Pharmaceuticals
ARAMCHOL: CLINICAL TRIALS AND ITS ENDPOINTS
Figure 4
Galmed Pharmaceuticals
PHIIA RESULTS: CHANGES IN CHOLESTEROL AND SERUM ADIPONECTIN LEVELS
Figure 5
Galmed Pharmaceuticals
CHANGES IN THE LEVELS OF CHOLESTEROL CRYSTALLIZATION AFTER THE ADDITION OF ARAMCHOL
Figure 1
Genfit SA
GOLDEN-505: COMPARISON WITH OTHER PHII STUDIES
Figure 2
Genfit SA
GOLDEN-505: COMPARISON WITH OTHER PHII STUDIES
Figure 3
Genfit SA
ELAFIBRANOR: PPAR??? REGULATES NUMEROUS PATHWAYS ESSENTIAL IN NASH
Figure 4
Genfit SA
ELAFIBRANOR: PHASE III TRIAL DESIGN
Figure 5A
Genfit SA
GOLDEN-505: IMPROVEMENT IN CARDIO-METABOLIC AND GLYCEMIC PARAMETERS
Figure 6
Genfit SA
EFFICACY OF GFT505 IN ANIMAL MODELS OF NAFLD/ NASH AND LIVER FIBROSIS
Figure 7
Genfit SA
EFFICACY OF GFT505 IN ANIMAL MODELS OF NAFLD/ NASH AND LIVER FIBROSIS
Figure 8
Genfit SA
EFFECTS OF GFT505 IN RATS WITH ESTABLISHED HEPATIC FIBROSIS
Figure 1
Intercept Pharmaceuticals
GLOBAL PBC PATIENT WATERFALL
Figure 2
Intercept Pharmaceuticals
FLINT STUDY RESULTS: IMPROVEMENT IN NAS, FIBROSIS, AND NASH RESOLUTION
Figure 3
Intercept Pharmaceuticals
FXR IS CENTRAL TO A MULTITUDE OF PATHWAYS
Figure 4
Intercept Pharmaceuticals
POOLED DATA IN PBC: ABSOLUTE AND PERCENT REDUCTION IN ALP
Figure 5
Intercept Pharmaceuticals
POISE STUDY: MET THE PRIMARY ENDPOINT AS EARLY AS 2 WEEKS
Figure 6
Intercept Pharmaceuticals
FLINT STUDY: RESPONSE RATES, FIBROSIS IMPROVEMENT, AND PROGRESSION IN HIGH-RISK PATIENT GROUPS
Figure 7
Intercept Pharmaceuticals
FLINT STUDY: RESPONSE RATES, FIBROSIS IMPROVEMENT, AND PROGRESSION IN HIGH-RISK PATIENT GROUPS
Figure 8
Intercept Pharmaceuticals
HEALTH ECONOMICS MODELLING FOR PBC AND LIVER DISEASE
Figure 9
Intercept Pharmaceuticals
PIPELINE PORTFOLIO
Figure 1
Tobira Therapeutics
CENTAUR - PHIIB CLINICAL TRIAL VS. OTHER PUBLISHED PHIIB STUDIES IN NASH
Figure 2
Tobira Therapeutics
CENICRIVIROC (CVC): A POTENT INHIBITOR OF INFILTRATION OF PRO-INFLAMMATORY MONOCYTES
Figure 3
Tobira Therapeutics
CENICRIVIROC (CVC): NASH MOUSE MODEL - REDUCTION IN FIBROSIS AND NAFLD ACTIVITY SCORE (NAS)
Figure 4
Tobira Therapeutics
CENICRIVIROC (CVC): LIPID PROFILE - CHANGES FROM BASELINE
Figure 5
Tobira Therapeutics
CENICRIVIROC (CVC): LIPID PROFILE - CHANGES FROM BASELINE
Figure 6
Tobira Therapeutics
CENICRIVIROC (CVC): PRODUCT PIPELINE
Chart 1:
Daiichi Sankyo
Efficacy comparison of Quizartinib vs. ASP-2215
Chart 4
Daiichi Sankyo
New NOAC share vs. Warfarin- Warfarin still holds >60% share in US
New NOAC share vs. Warfarin- Warfarin still holds >60% share in US
iichi Sankyo
US TRX of each NOAC since launch
Global Subcutaneous Immunoglobulins Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
Published: 26-Sep-2023 Price: US 3380 Onwards Pages: 113
Market Overview of Global Subcutaneous Immunoglobulins market:
According to our latest research, the global Subcutaneous Immunoglobulins market looks promising in the next 5 years. As of 2022, the global Subcutaneous Immunoglobulins market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years.
Immunoglobulin therapy, also known as normal human immunoglobulin (NHIG), is the use of a mixture of antibo......
Global Flu Vaccine Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
Published: 26-Sep-2023 Price: US 3380 Onwards Pages: 105
Market Overview of Global Flu Vaccine market:
According to our latest research, the global Flu Vaccine market looks promising in the next 5 years. As of 2022, the global Flu Vaccine market was estimated at USD 5696.99 million, and it's anticipated to reach USD 8228.7 million in 2028, with a CAGR of 6.32% during the forecast years.
The flu, also known as the flu, is an infectious respiratory disease. A disease caused by an influenza virus that infects the nose, throat, and som......
Global Axitinib Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
Published: 26-Sep-2023 Price: US 3380 Onwards Pages: 107
Market Overview of Global Axitinib market:
According to our latest research, the global Axitinib market looks promising in the next 5 years. As of 2022, the global Axitinib market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years.
Axitinib is a small molecule tyrosine kinase inhibitor developed by Pfizer.
This report covers a research time span from 2018 to 2028, and presents a de......
Global Brain Health Supplements Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
Published: 26-Sep-2023 Price: US 3380 Onwards Pages: 104
Market Overview of Global Brain Health Supplements market:
According to our latest research, the global Brain Health Supplements market looks promising in the next 5 years. As of 2022, the global Brain Health Supplements market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years.
This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global......
Global Propofol Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
Published: 26-Sep-2023 Price: US 3380 Onwards Pages: 99
Market Overview of Global Propofol market:
According to our latest research, the global Propofol market looks promising in the next 5 years. As of 2022, the global Propofol market was estimated at USD 877.0 million, and it's anticipated to reach USD 1101.49 million in 2028, with a CAGR of 3.87% during the forecast years.
Propofol is a prescription, injectable anesthetic drug used to decrease the activity of brain and central nervous system. It is administered intravenously an......
2023-2031 Report on Global Analgesics Market by Player, Region, Type, Application and Sales Channel
Published: 26-Sep-2023 Price: US 2500 Onwards Pages: 89
This report studies the Analgesics market, covering market size for segment by type (Opioid, Non-opioid, etc.), by application (Hospital Pharmacies, Retail Pharmacies, etc.), by sales channel (Direct Channel, Distribution Channel), by player (Bayer AG, Endo International plc, Assertio Holdings, Inc., Janssen Global Services, LLC, GSK plc, etc.) and by region (North America, Europe, Asia-Pacific, South America and Middle East & Africa).
This report provides detailed historical anal......
Global Oral Proteins and Peptides Market Insights, Forecast to 2029
Published: 25-Sep-2023 Price: US 4900 Onwards Pages: 86
Polypeptide and protein drugs refer to the biological drugs of polypeptide and protein substances used for prevention,treatment and diagnosis.Polypeptide is a compound formed by linking a-amino acids together with a peptide chain,and it is also an intermediate product of proteolysis.N polypeptide chains are entangled in a certain spatial structure to form a protein.The hydrolysis of macromolecular proteins produces polypeptides.Such drugs are biochemical preparations and have relatively strict r......
Global Orphan Drugs Market Insights, Forecast to 2029
Published: 25-Sep-2023 Price: US 4900 Onwards Pages: 106
An orphan drug is a pharmaceutical agent developed to treat medical conditions which, because they are so rare, would not be profitable to produce without government assistance. The conditions are referred to as orphan diseases.
Market Analysis and Insights: Global Orphan Drugs Market
The global Orphan Drugs market is projected to grow from US$ 153130 million in 2023 to US$ 269210 million by 2029, at a Compound Annual Growth Rate (CAGR) of 9.9% during the forecast period.
Br......
Global Inosine Pranobex Market Insights, Forecast to 2029
Published: 22-Sep-2023 Price: US 4900 Onwards Pages: 112
Inosine pranobex (BAN; also known as inosine acedoben dimepranol (INN) or methisoprinol) an antiviral drug that is a combination of inosine and dimepranol acedoben (a salt of acetamidobenzoic acid and dimethylaminoisopropanol) in a ratio of 1 to 3. Inosine pranobex has no effect on viral particles itself. Instead, it acts as an immunostimulant, an analog of thymus hormones. It is most commonly used to treat the rare measles complication subacute sclerosing panencephalitis in conjunction with int......
SERVICES
Value for Money
We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
Ever Growing Inventory
Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
One Stop Solution
Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
Dedicated Client Engagement
Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
Saving Time and Efforts
Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
Payment Flexibility
Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
Post-Purchase Research Support
Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements.
Subscription Offers & Packages (Get in touch with us for more details -
[email protected] / +1 888 391 5441 )
- Ad Hoc
-
- Pay - as - you - go / Bucket Subscriptions
- Fixed Cost for #of reports
- Customize / Personalize as per your needs
